Article thumbnail

Clostridium difficile--a moving target

By Glenn S. Tillotson and Joni Tillotson


Clostridium difficile has been recognized as a pathogen in humans for over 40 years, but in the past decade the incidence has increased and, more importantly, the clinical presentation and consequences have become more serious, with increased morbidity and mortality. The emergence of a new, more pathogenic strain, BI/NAP1/027, has driven these shifts. Treatment of this disease has been with two antibiotics, metronidazole and vancomycin, but increasing recurrence, not uncommon with C. difficile infections, has prompted research into several alternative therapies. These include a new class of antibiotic (fidaxomicin), a monoclonal antibody, a vaccine, and most recently a biotherapeutic (which, in this case, is a nontoxin-producing strain of C. difficile). The future management of C. difficile infection will probably require a combination of these approaches once we have the data from ongoing studies

Topics: Review Article
Publisher: Faculty of 1000 Ltd
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2010). ACAM-CDIFF™: An active vaccine against Clostridium difficile infection [abstract].
  2. (2010). Ambrosino DM: Treatment with monoclonal antibodies against Clostridium difficile toxins.
  3. (2010). Clostridia as agents of zoonotic disease. Vet Microbiol
  4. (1997). Clostridium difficile infections among hospitalized children, United Sates,
  5. (1991). D: Clostridium difficile-associated diarrhea in a region of Quebec from
  6. (2006). DB: Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis
  7. (2007). DM: The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol
  8. (2010). Efficacy and safety of fidaxomicin (FDX) vs. vancomycin in Clostridium difficile infection (CDI) in 2 randomized Page 6 of 7 (page number not for citation purposes)
  9. (2010). Emerg Infect Dis
  10. (2005). Gerding DN: An epidemic, toxin genevariant strain of Clostridium difficile.
  11. (2010). Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection.
  12. (2007). MB: A comparison of vancomcyin and metronidazole for the treatement of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis
  13. (2005). Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin Infect Dis
  14. (2010). MH: The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev
  15. (2010). Monnot-Chase E: Phase I evaluation of an oral suspension of VP 20621, spores of an non-toxigenic C. difficile strain (NTCD) in healthy older subjects pretreated with oral vancomycin [abstract].
  16. (2010). NP: The role of toxin A and toxin B in Clostridium difficile infection. Nature
  17. (2007). Results of a phase III trial comparing tolevamer, vancomycin and metronidazole inpatients with Clostridium difficile-associated diarrhea (CDAD) [abstract].
  18. (2009). Statistical bulletin–Deaths involving Clostridium difficile: England & Wales,
  19. (2010). Tate EW: Chemical probes of surface layer biogenesis in Clostridium difficile.
  20. (2009). Toxin B is essential for virulence of Clostridium difficile.
  21. (2010). TV: Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Inf Dis
  22. (2010). Vedantam G: Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production.
  23. (2009). Yokoe DS: Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis